Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CAWIM
ADC Name
WO2020063676A1 ADC-29
Synonyms
WO2020063676A1_ADC 29
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Glioblastoma [ICD11:2A00]
Investigative
Oropharynx squamous cell carcinoma [ICD11:2B6A]
Investigative
Drug-to-Antibody Ratio
7.24
Structure
Antibody Name
1F9DS
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2020063676A1_ADC-29 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 72.27
%
Detroit 562 cells
Pharyngeal squamous cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 72.27% (Day 28) Positive CD276 expression (CD276 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p., qw*3 of one of the conjugates listed above or with PBS only.
In Vivo Model Detroit 562 CDX model
In Vitro Model Pharyngeal squamous cell carcinoma Detroit 562 cells CVCL_1171
References
Ref 1 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.